古賀 貴子
Takako Koga, Ph.D.
東京大学大学院医学系研究科 免疫学 特任助教
JST ERATO 高柳オステオネットワークプロジェクト グループリーダー
E-mail address: koga-im[@]m.u-tokyo.ac.jp
原著論文、総説・著書（英文)
Kim, H., Kim, T., Jeong, B.C., Cho, I.T., Han, D., Takegahara, N., Negishi-Koga, T., Takayanagi, H., Lee, J.H., Sul, J.Y., Prasad, V., Lee, S.H., Choi, Y..
Tmem64 modulates calcium signaling during RANKL-mediated osteoclast differentiation. Cell Metab. 17(2):249-60 (2013) [PubMed]
Fujita, K., Iwasaki, M., Ochi, H., Fukuda, T., Ma, C., Miyamoto, T., Takitani, K., Negishi-Koga, T., Sunamura, S., Kodama, T., Takayanagi, H., Tamai, H., Kato, S., Arai, H., Shinomiya, K., Itoh, H., Okawa, A., Takeda, S.
Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med. 18(4):589-94 (2012) [PubMed]
Tsuji-Takechi, K., Negishi-Koga, T., Sumiya, E., Kukita, A., Kato, S., Maeda, T., Pandolfi, P.P., Moriyama, K., Takayanagi, H.
Stage-specific functions of leukemia/lymphoma-related factor (LRF) in the transcriptional control of osteoclast development. Proc Natl Acad Sci U S A. 109(7):2561-6(2012) [PubMed]
Negishi-Koga, T., Shinohara, M., Komatsu, N., Bito, H., Kodama, T., Friedel H, R., Takayanagi, H.
Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 17, 1473-80(2011) [PubMed]
Barrow, A. D., Raynal, N., Andersen T, L., Slatter D, A., Bihan, D., Pugh, N., Cella, M., Kim, T., Rho, J., Negishi-Koga, T., Delaisse J, M., Takayanagi, H., Lorenzo, J., Colonna, M., Farndale R, W., Choi, Y., Trowsdale, J.
OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest. 121(9):3505-16 (2011) [PubMed]
Taguchi, Y., Gohda, J., Koga, T., Takayanagi, H. and Inoue, J.
A unique domain in RANK is required for Gab2 and PLCgamma2 binding to establish osteoclastogenic signals. Genes Cells. 14(11), 1331-45 (2009) [PubMed]
Negishi-Koga, T. and Takayanagi, H.
Ca2+ -NFATc1 signaling is an essential axis of osteoclast differentiation. Immunological Reviews. 231(1):241-56 (2009) --- Review [PubMed]
Zhao, B., Takami, M., Yamada, A., Wang, X., Koga, T., Hu, X., Tamura, T., Ozato, K., Choi, Y., Ivashkiv, L. B., Takayanagi, H. and Kamijo, R.
Interferon Regulatory Factor-8 Regulates Bone Metabolism by Suppressing Osteoclastogenesis. Nat Med. 15(9):1066-71 (2009) [PubMed]
Negishi-Koga, T. and Takayanagi, H.
Mysteries in Ca2+ signaling during osteoclast differentiation.IBMS BoneKEy (2009) 6, 301-306 (2009) --- Review [link]
Mori, Y., Tsuji, S., Inui, M., Sakamoto, Y., Endo, S., Ito, Y., Fujimura, S., Koga, T., Nakamura, A., Takayanagi, H., Itoi, E. and Takai, T.
Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development. J Immunol. 181(7):4742-51 (2008) [PubMed]
Shinohara, M., Koga, T., Okamoto, K., Sakaguchi, S., Arai, K., Yasuda, H., Takai T., Kodama T., Morio T., Geha, R.S., Kitamura, D., Kurosaki, T., Ellmeier W., Takayanagi, H.
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 132(5):794-806 (2008) [PubMed]
Ochi, S., Shinohara, M., Sato, K., Gober H.J., Koga, T., Kodama, T., Takai T., Miyasaka N., Takayanagi H.
Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc Natl Acad Sci USA. 104(27):11394-9 (2007) [PubMed]
Koga, T., Matsui, Y., Asagiri, M., Kodama, T., de Crombrugghe, B., Nakashima K. & Takayanagi, H.
NFAT and Osterix cooperatively regulate bone formation. Nat Med. 11(8):880-5 (2005) [PubMed]
Gohda, J., Akiyama, T., Koga, T., Takayanagi, H., Tanaka, S. and Inoue, J.
RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J. 24(4):790-9 (2005) [PubMed]
Takayanagi, H., Kim, S., Koga, T. and Taniguchi, T.
Stat1-mediated cytoplasmic attenuation in osteoimmunology. J Cell Biochem. 94(2):232-40 (2005)---Review [PubMed]
Koga, T., Inui, M., Inoue, K., Kim, S., Suematsu, A., Kobayashi, E., Iwata, T., Ohnishi, H., Matozaki, T., Kodama, T., Taniguchi, T., Takayanagi, H.*, and Takai, T.*(*Corresponding authors)
Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428(6984):758-63 (2004) [PubMed]
Urushibara, M.*, Takayanagi, H.*, Koga, T., Kim, S., Isobe, M., Morishita, Y., Nakagawa, T., Loeffler, M., Kodama, T., Kurosawa, H., and Taniguchi, T. (*Equal contributors)
The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-κB ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum. 50(3):794-804 (2004) [PubMed]
Kim, S., Koga, T., Isobe, M., Kern, B. E., Yokochi, T., Chin, Y.E., Karsenty, G., Taniguchi, T., and Takayanagi, H.
Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation. Genes Dev. 94(2):232-40 (2003) [PubMed]
Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J, Wagner, E. F., Mak, T. W., Kodama, T., and Taniguchi, T.
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 3(6):889-901 (2002) [PubMed]
総説/著書（和文）
根岸‐古賀 貴子、 高柳 広：Bone metabolism 羊土社 シグナル伝達イラストマップ 改定版、2012
古賀貴子、高柳広：骨粗鬆症に対する抗体治療
医学のあゆみ, 238(6): 730-37, 2011
古賀貴子、高柳広：第４章 － 骨吸収のメカニズム－破骨細胞の分化と活性化機構
わかる実験医学シリーズ 骨研究がわかる～シグナル研究から広がる骨代謝と生体制御のクロストーク～
羊土社 : 49-57、2010
古賀貴子、高柳広：骨免疫学研究の歴史とup to date
リウマチ科 40(2)：105-111，2008
古賀貴子、高柳広：Osteoimmunology
内分泌・糖尿病科 23（suppl.3）150-158、2006
古賀貴子、高柳広：骨代謝におけるFK506の作用機序
医学のあゆみ 219（4）291-292、2006
古賀貴子、高柳広：骨吸収と骨形成におけるNFATc1の働き
THE BONE 20（3） 75(335)-81(341)、2006
古賀貴子、高柳広：免疫グロブリン様受容体による骨破壊の制御
臨床免疫 44（3） 267-275、2005
古賀貴子、高柳広：骨吸収のメカニズム－破骨細胞の分化と活性化機構－
骨研究がわかる、49-57、2005
